You are here

  • Home
  • Archive
  • Volume 67, Issue 2
  • The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy

Article Text

Article menu
Download PDFPDF
Extended report
The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy
  1. D van der Heijde6,
  2. G Burmester1,
  3. J Melo-Gomes2,
  4. C Codreanu3,
  5. E Martin Mola4,
  6. R Pedersen5,
  7. B Freundlich5,
  8. D J Chang5,
  9. for the Etanercept Study 400 Investigators
  1. 1
    Charité Hospital, Humboldt University, Berlin, Germany
  2. 2
    SERVIMED, Lisbon, Portugal
  3. 3
    Centrul de Boli Reumatismale, Bucharest, Romania
  4. 4
    Hospital La Paz, Madrid, Spain
  5. 5
    Wyeth Research, Collegeville, PA, USA
  6. 6
    Leiden University Medical Center, Leiden, The Netherlands
  1. Désirée van der Heijde, Leiden University Medical Center, PO Box 9600, 2300RC Leiden, The Netherlands; d.vanderheijde{at}kpnplanet.nl

Abstract

Objective: To determine if adding etanercept (ETN) to methotrexate (MTX) or MTX to ETN for 52 weeks in rheumatoid arthritis (RA) patients with moderate disease activity provides higher efficacy.

Methods: All patients (n = 227) received open-label ETN 25 mg subcutaneously twice-weekly and MTX orally up to 20 mg weekly for 52 weeks and had completed a 3-year study in which patients received MTX, ETN or combination therapy. Endpoints were based on Disease Activity Score (DAS) and European League Against Rheumatism (EULAR) responses.

Results: Patients previously receiving combination therapy (Combination group; n = 96) had a lower disease activity at baseline. The mean DAS for those previously receiving MTX (ETN-added group; n = 55) and previously receiving ETN (MTX-added group; n = 76) were in the moderate disease activity range at baseline; Combination patients had a low disease activity. The greatest increase in DAS remission rates from baseline to week 52 was in the ETN-added group (23.6% to 41.8%, p<0.01), although Combination (37.6% to 50.0%, p<0.01) and MTX-added (26.7% to 36.8%, p = NS) also demonstrated improvements. DAS low disease activity and EULAR responses showed similar results. No new safety issues were identified.

Conclusion: RA patients who were partial responders to long-term MTX or etanercept monotherapy obtained a higher efficacy with combination therapy. Responses achieved by patients with combination therapy after 3 years in the previous study were sustained or improved during the fourth year of treatment. This trial supports the higher therapeutic effect of combination treatment with etanercept and MTX in RA patients with moderate disease activity despite monotherapy with one of the two agents.

http://dx.doi.org/10.1136/ard.2007.076166

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding: This study was supported by Wyeth Pharmaceuticals (Collegeville, PA).

    • Competing interests: DvdH, GB, JM-G, CC, and EMM participated as investigators, consultants, or both to Wyeth. DvdH was reimbursed by Wyeth, the manufacturer of etanercept, for attending several conferences and for running educational programmes. EMM has received fees as a consultant of Abbott, Centocor, Schering-Plough, and Bristol Myers Squibb. RP, BF and DC are employed by and have stock options with Wyeth Pharmaceuticals.